Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, has announced that it will release its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide a corporate update. Investors and interested parties can access the webcast through Liquidia's website. For those unable to attend the live event, a rebroadcast will be available and archived for one year on the company's website.
Liquidia (NASDAQ: LQDA), un'azienda biofarmaceutica focalizzata sullo sviluppo di terapie innovative per malattie cardiopolmonari rare, ha annunciato che pubblicherà i risultati finanziari del secondo trimestre 2024 il 7 agosto 2024. L'azienda ospiterà un webcast dal vivo alle 8:30 a.m. Eastern Time nello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale. Gli investitori e gli interessati possono accedere al webcast tramite il sito web di Liquidia. Per coloro che non possono partecipare all'evento in diretta, una registrazione sarà disponibile e archiviata per un anno sul sito dell'azienda.
Liquidia (NASDAQ: LQDA), una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades cardiopulmonares raras, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024. La empresa llevará a cabo un webcast en vivo a las 8:30 a.m. hora del Este el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa. Los inversionistas y las partes interesadas pueden acceder al webcast a través del sitio web de Liquidia. Para aquellos que no puedan asistir al evento en vivo, se hará una retransmisión disponible y archivada durante un año en el sitio web de la empresa.
리퀴디아 (NASDAQ: LQDA)는 희귀 심폐 질환을 위한 혁신적인 치료법 개발에 주력하는 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 7일에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 라이브 웹캐스트를 진행하여 재무 결과를 논의하고 기업 업데이트를 제공할 예정입니다. 투자자 및 이해관계자는 리퀴디아의 웹사이트를 통해 웹캐스트에 접근할 수 있습니다. 라이브 이벤트에 참석하지 못하는 분들을 위해, 재방송은 회사 웹사이트에서 1년 동안 아카이브됩니다.
Liquidia (NASDAQ: LQDA), une entreprise biopharmaceutique axée sur le développement de thérapies innovantes pour les maladies cardiopulmonaires rares, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 7 août 2024. L'entreprise organisera un webinaire en direct à 8h30, heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour de l'entreprise. Les investisseurs et les parties intéressées peuvent accéder au webinaire via le site Web de Liquidia. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion sera disponible et archivée pendant un an sur le site de l'entreprise.
Liquidia (NASDAQ: LQDA), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien für seltene kardiopulmonale Erkrankungen spezialisiert hat, hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024 am 7. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time ein Live-Webcast veranstalten, um die finanziellen Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Investoren und Interessierte können auf den Webcast über die Website von Liquidia zugreifen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Wiederholung verfügbar sein und für ein Jahr auf der Unternehmenswebsite archiviert.
- None.
- None.
MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia (LQDA) report its Q2 2024 financial results?
What time is Liquidia's (LQDA) Q2 2024 earnings webcast scheduled for?
Where can I access Liquidia's (LQDA) Q2 2024 earnings webcast?
How long will Liquidia's (LQDA) Q2 2024 earnings webcast be available for replay?
